The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation

British Journal of Haematology

Volumn 118, Issue 4, 2002, Pages 1124-1127

  Ronghe, Milind D ^a   Foot, Annabel B M ^a   Cornish, Jaqueline M ^a   Steward, Colin G ^a   Carrington, David ^b   Goulden, Nicholas ^a   Marks, David I ^a   Oakhill, Anthony ^a   Pamphilon, Derwood H ^a  

^a BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Cytomegalovirus disease; Leucodepletion; Platelet concentrates; Stem cell transplantation; Transfusion

Indexed keywords

ACICLOVIR; FOSCARNET; IMMUNOGLOBULIN; THROMBOCYTE CONCENTRATE;

ADULT; ARTICLE; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ERYTHROCYTE; FEMALE; HUMAN; IMMUNOFLUORESCENCE TEST; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SERODIAGNOSIS; STEM CELL TRANSPLANTATION;

ACYCLOVIR; ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOSCARNET; GANCICLOVIR; HUMANS; INFANT; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PLATELET TRANSFUSION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036049078     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03746.x     Document Type: Article

References (12)

1. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
2. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks
3. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
4. Cytomegalovirus infection in recipients of related and unrelated donor bone marrow transplants: No evidence of increased incidence in patients receiving unrelated donor grafts
5. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
6. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome
7. Transfusion of the HIV-seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5), and HHV-6, 7, and 8
8. Post marketing surveillance
9. Risk factors for cytomegalovirus infection after human marrow transplantation
10. Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study
11. Prevention of transfusion-transmitted cytomegalovirus infection
12. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions